BILIARY TRACT CANCER

This study tested whether the immunotherapy drug nivolumab could help control advanced bile duct cancer that had stopped responding to standard chemotherapy. The trial enrolled 54 adults whose cancer had progressed after one or two prior treatments. Researchers measured whether t…

This study tested whether an oral medicine called BI 907828 could help control advanced cancers of the bile duct, pancreas, lung, or bladder that had a specific genetic pattern (MDM2 amplified, TP53 wild-type) and had stopped responding to standard treatments. All 99 participants…

This study tested whether a combination of three drugs—capecitabine (a chemotherapy pill), lenvatinib (a targeted therapy), and tislelizumab (an immunotherapy)—could help prevent cancer from coming back in people who had surgery to remove bile duct cancer. The trial involved 65 p…

This study tested if a new combination of chemotherapy drugs (nal-IRI with 5-FU) could better control advanced bile duct cancer compared to a standard treatment. It involved 93 adults whose cancer could not be removed by surgery. The main goal was to see if the new combination co…

This study tested a combination of four drugs for people with advanced bile duct cancer that had worsened after their first treatment. The main goals were to see if the drug mix was safe and if it could help control the cancer and extend life. It involved 34 participants and comb…

This study monitored the safety of a drug called IMFINZI when used with standard chemotherapy in 236 patients with advanced bile duct cancer that cannot be removed by surgery. It was conducted in Japan after the treatment was approved, to better understand the real-world side eff…

This study tested a combination of three drugs (a chemotherapy, an immunotherapy, and a blood vessel blocker) for people with advanced bile duct cancer whose disease progressed after one prior treatment. The goal was to see if this combination could shrink tumors and control the …

This study looked back at the medical records of 730 patients in Japan with advanced bile duct cancer who received standard drug treatment. Researchers wanted to understand if serious bile duct complications that required hospital stays affected how long patients could continue t…

This study tested two short questionnaires to see if they could predict which older patients (65+) with digestive cancers would experience severe side effects from chemotherapy. Researchers followed 72 patients to see if their scores on these frailty checklists matched up with wh…

This study created a permanent registry to collect information from people with bile duct cancer in Germany. It tracked what treatments patients received, how they felt, and how the disease progressed, but did not test any new treatments. The goal was to gather real-world data to…